Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Citi
US Army
Chinese Patent Office
Accenture
Cipla
Fish and Richardson
Argus Health
Merck

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,283,197

« Back to Dashboard

Which drugs does patent 9,283,197 protect, and when does it expire?

Patent 9,283,197 protects EPINEPHRINE and is included in one NDA.
Summary for Patent: 9,283,197
Title:More potent and less toxic formulations of epinephrine and methods of medical use
Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine.
Inventor(s): Taneja; Jugal K. (Tampa, FL)
Assignee:
Application Number:14/460,845
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 9,283,197

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Belcher Pharms Llc EPINEPHRINE epinephrine SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 205029-001 Jul 29, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK ➤ Try a Free Trial
Belcher Pharms Llc EPINEPHRINE epinephrine SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 205029-001 Jul 29, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS ➤ Try a Free Trial
Belcher Pharms Llc EPINEPHRINE epinephrine SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS 205029-001 Jul 29, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Chinese Patent Office
Fuji
Dow
US Army
Teva
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.